IP Library Granted Patent US 11,701,379
Granted Patent B2
US 11,701,379 · App. 17/041,399 · Granted Jul 18, 2023

In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces

Inventors: Qian Chen (Barrington, RI); Yupeng Chen (Sharon, MA); Hongchuan Yu (Chestnut Hill, MA)
Assignee: Rhode Island Hospital
A61K31/713A61K47/545A61K47/6929A61K47/6949A61P19/02C12N15/1136C12N2310/141C12N2320/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,701,379
App. No.
17/041,399
Granted
Jul 18, 2023
Kind
B2
Abstract

The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

Claims (12)

1. A method of treating rheumatoid arthritis comprising the systemic administration of an effective amount of a rosette nanopiece and a nucleic acid, wherein said nanopiece comprises a compound of Formula I or Formula II,

or a salt thereof,

wherein,

X is CH or N;

R 2 is hydrogen or a linker group;

Y is absent when R 2 is hydrogen or is an amino acid or polypeptide;

R 1 is hydrogen or aliphatic,

wherein the amino acid side chain is selected from:

wherein, the compounds of Formula (I), Formula (II), or a salt thereof, or a combination of Formula (I) and Formula (II) self-assemble to form a nanotube, and

wherein the nucleic acid comprises an siRNA selected from the group consisting of TNF-α siRNA, a sequence comprising AAG CCT GTA GCC CAC GTC GTA (SEQ ID NO: 229), a sequence comprising GGC ACC ACT AGT TGG TTG TCT TTG (SEQ ID NO: 230), an anti-miR-181a comprising SEQ ID NO: 228, and an anti-miR-181a comprising SEQ ID NO: 229.

2. The method of claim 1 , wherein the nanopiece comprises a compound selected from

or a salt thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 17, 2023
From: RHODE ISLAND HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065257/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2020
From: CHEN, QIAN; CHEN, YUPENG; YU, HONGCHUAN
To: RHODE ISLAND HOSPITAL
Reel/Frame 054337/0777 →
Continuity (2)
Provisional Application 62648233 · Mar 26, 2018
Related Publication 20210023117A1 · Jan 28, 2021